|
Oct 9
|
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 8
|
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
|
|
Sep 25
|
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
|
|
Jul 26
|
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
|
|
Jul 23
|
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
Jun 11
|
SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
|
|
Jun 11
|
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
|
|
May 24
|
Seastar touts positive case studies for selective cytopheretic device
|
|
May 22
|
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
|
|
Mar 12
|
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
|
|
Mar 11
|
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
|
|
Mar 6
|
Q4 2023 Nuwellis Inc Earnings Call
|
|
Jan 11
|
SeaStar Medical Appoints David A. Green as Chief Financial Officer
|
|
Jan 9
|
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
|
|
Dec 28
|
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
|
|
Aug 22
|
SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time
|